To evaluate whether characteristics in the tumor tissue or the blood, agnostic of tumor type, correlate with clinical response and tumoral CD8 conversion, we performed comprehensive multiomic analyses on pre- and on-treatment tumor and blood samples. This evidence concerns the gene CD8A and neoplasm.